Cardiovascular prevention: Lifestyle and statins - Competitors or companions?

South African Medical Journal

Volumn 104, Issue 3, 2014, Pages 168-173

  Opie, Lionel Henry ^a   Dalby, Anthony John ^b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MILPARK HOSPITAL   (South Africa)

Author keywords

Beneficial lifestyle; Cardiovascular disease prevention; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AMNESIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM EXAMINATION; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIET; EXERCISE; FRAMINGHAM RISK SCORE; HUMAN; LIFESTYLE MODIFICATION; LOW CALORY DIET; LOW FAT DIET; MEDITERRANEAN DIET; MORTALITY; MYALGIA; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; REVIEW;

CARDIOVASCULAR DISEASES; DIET; EXERCISE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE;

EID: 84894813042     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/SAMJ.7942     Document Type: Review

References (47)

1. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013. [http://dx.doi.org/10.1161/01.cir.0000437738.63853.7a]
2. Chiuve SE, McCullough ML, Sacks FM, Rimm EB. Healthy lifestyle factors in the primary prevention of coronary heart disease among men: Benefits among users and nonusers of lipid-lowering and antihypertensive medications. Circulation 2006;114(2):160-167. [http://dx.doi.org/10.1161/CIRCULATIONAHA.106.621417]
3. Chiuve SE, Rexrode KM, Spiegelman D, Logroscino G, Manson JE, Rimm EB. Primary prevention of stroke by healthy lifestyle. Circulation 2008;118(9):947-954. [http://dx.doi.org/10.1161/CIRCULATIONAHA.108.781062]
4. Van Dam RM, Li T, Spiegelman D, Franco OH, Hu FB. Combined impact of lifestyle factors on mortality: Prospective cohort study in US women. BMJ 2008;337:a1440. [http://dx.doi.org/10.1136/bmj.a1440]
5. Dong C, Rundek T, Wright CB, Anwar Z, Elkind MS, Sacco RL. Ideal cardiovascular health predicts lower risks of myocardial infarction, stroke, and vascular death across whites, blacks, and hispanics: The northern Manhattan study. Circulation 2012;125(24):2975-2984. [http://dx.doi.org/10.1161/CIRCULATIONAHA.111.081083]
6. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 2011;364:2392-2404. [http://dx.doi.org/10.1056/NEJMoa1014296]
7. Yates T, Haffner SM, Schulte PJ, et al. Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis. Lancet 2013. [http://dx.doi.org/10.1016/S0140-6736(13)62061-9]
8. Piepoli MF, Davos C, Francis DP, Coats AJ; ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328:189-196. [http://dx.doi.org/10.1136/bmj.37938.654220.EE]
9. Posel D, Noakes T, Kantor P, Lambert M, Opie LH. Exercise training after experimental myocardial infarction increases the ventricular fibrillation threshold before and after the onset of reinfarction in the isolated rat heart. Circulation 1989;80(1):138-145. [http://dx.doi.org/10.1161/01.CIR.80.1.138]
10. Noakes TD, Opie LH, Rose AG, Kleynhans PH, Schepers NJ, Dowdeswell R. Autopsy-proved coronary atherosclerosis in marathon runners. N Engl J Med 1979;301(2):86-89. [http://dx.doi.org/10.1056/NEJM197907123010205]
11. Kokkinos PF, Faselis C, Myers J, Panagiotakos D, Doumas M. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: A cohort study. Lancet 2013;381:394-399. [http://dx.doi.org/10.1016/S0140-6736(12)61426-3]
12. Kujala UM, Mäkinen VP, Heinonen I, et al. Long-term leisure-time physical activity and serum metabolome. Circulation 2013;127(3):340-348. [http://dx.doi.org/10.1161/CIRCULATIONAHA.112.105551]
13. Mozaffarian D, Hao T, Rimm EB, Willett WC, Hu FB. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med 2011;364(25):2392-2404. [http://dx.doi.org/10.1056/NEJMoa1014296]
14. Shai I, Schwarzfuchs D, Henkin Y, et al; Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008;359(3):229-241. [http://dx.doi.org/10.1056/NEJMoa070868]
15. Noakes TD, Creed S-A, Proudfoot J, Grier D. The Real Meal Revolution. Cape Town: Quivertree Publications, 2013.
16. Noakes M, Foster PR, Keogh JB, James AP, Mamo JC, Clifton PM. Comparison of isocaloric very low carbohydrate/high saturated fat and high carbohydrate/low saturated fat diets on body composition and cardiovascular risk. Nutr Metab (Lond) 2006;3:7. [http://dx.doi.org/10.1186/1743-7075-3-7]
17. Noakes TD. Low-carbohydrate and high-fat intake can manage obesity and associated conditions: Occasional survey. S Afr Med J 2013;103(11):826-830. [http://dx.doi.org/10.7196/SAMJ.7302]
18. Poulsen SK, Due A, Jordy AB, et al. Health effect of the New Nordic Diet in adults with increased waist circumference: A 6-mo randomized controlled trial. Am J Clin Nutr 2014;99(1):35-45. [http://dx.doi.org/10.3945/ajcn.113.069393]
19. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003;348(26):2599-2608. [http://dx.doi.org/10.1056/NEJMoa025039]
20. Estruch R, Ros E, Salas-Salvadó J, et al; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet N Engl J Med 2013;368:1279-1290. [http://dx.doi.org/10.1056/NEJMoa1200303]
21. Opie LH. Mediterranean diet for primary prevention of cardiovascular disease. N Engl J Med 2013;369:672-677. [http://dx.doi.org/10.1056/NEJMc1306659]
22. Bao Y, Han J, Hu FB, et al. Association of nut consumption with total and cause-specific mortality. N Engl J Med 2013;369:2001-2011. [http://dx.doi.org/10.1056/NEJMoa1307352]
23. Shaodong C, Haihong Z, Manting L, Guohui L, Zhengxiao Z, Zhang YM. Research of influence and mechanism of combining exercise with diet control on a model of lipid metabolism rat induced by high fat diet. Lipids Health Dis 2013;12:21. [http://dx.doi.org/10.1186/1476-511X-12-21]
24. Arnold SV, Spertus JA, Masoudi FA, et al. Beyond medication prescription as performance measures: Optimal secondary prevention medication dosing after acute myocardial infarction. J Am Coll Cardiol 2013;62(19):1791-1801. [http://dx.doi.org/10.1016/j.jacc.2013.04.102]
25. Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-1278. [http://dx.doi.org/10.1016/S0140-6736(05)67394-1]
26. Klug E; South African Heart Association (S A Heart); Lipid and Atherosclerosis Society of Southern Africa (LASSA). South African Dyslipidaemia Guideline Consensus Statement. S Afr Med J 2012;102(3):178-187.
27. Ridker PM, Cook NR. Statins: New American guidelines for prevention of cardiovascular disease. Lancet 2013;382(9907):1762-1765. [http://dx.doi.org/10.1016/S0140-6736(13)62388-0]
28. Dorresteijn JA, Boekholdt SM, van der Graaf Y, et al. High-dose statin therapy in patients with stable coronary artery disease: Treating the right patients based on individualized prediction of treatment effect. Circulation 2013;127(25):2485-2493. [http://dx.doi.org/10.1161/CIRCULATIONAHA.112.000712]
29. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;1:CD004816. [http://dx.doi.org/10.1002/14651858.CD004816.pub5]
30. Puri R, Nissen SE, Libby P, et al. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation 2013;128(22):2395-2403. [http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004243]
31. Heart Advisor. October 2008. http://www.heart-advisor.com/issues/11_10/ (accessed 31 January 2014).
32. McGuinness B, Passmore PJ. Can statins prevent or help treat Alzheimer's disease? Alzheimers Dis 2010;20(3):925-933. [http://dx.doi.org/10.3233/JAD-2010-091570]
33. Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and cognition: A systematic review and meta-analysis of shortand long-term cognitive effects. Mayo Clin Proc 2013;88(11):1213-1221. [http://dx.doi.org/10.1016/j.mayocp.2013.07.013]
34. Tendolkar I, Enajat M, Zwiers MP, et al. 1-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: Evidence from a parallel group randomized trial. Int J Geriatr Psychiatry 2012;27(1):49-58. [http://dx.doi.org/10.1002/gps.2688]
35. Opie LH. Exercise-induced myalgia may limit the cardiovascular benefits of statins. Cardiovasc Drugs Ther 2013;27(6):569-572. [http://dx.doi.org/10.1007/s10557-013-6483-8]
36. Correale M, Totaro A, Passero T, et al. Treatment with atorvastatin is associated with a better prognosis in chronic heart failure with systolic dysfunction: Results from the Daunia Heart Failure Registry. Neth Heart J 2013;21(9):408-416. [http://dx.doi.org/10.1007/s12471-013-0430-y]
37. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. Lancet 2012;380(9841):565-571. [http://dx.doi.org/10.1016/S0140-6736(12)61190-8]
38. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet 2010;375(9716):735-742. [http://dx.doi.org/10.1016/S0140-6736(09)61965-6]
39. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: Weighing the evidence. J Am Coll Cardiol 2012;60(10):875-881. [http://dx.doi.org/10.1016/j.jacc.2012.07.007]
40. Ko DT, Wijeysundera HC, Jackevicius CA, et al. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins. Circ Cardiovasc Qual Outcomes 2013;6(3):315-322. [http://dx.doi.org/10.1161/CIRCOUTCOMES.111.000015]
41. Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: Effect of baseline risk factors for diabetes. J Am Coll Cardiol 2013;61(2):148-152. [http://dx.doi.org/10.1016/j.jacc.2012.09.042]
42. Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: Population based study. BMJ 2013;346:f2610. [http://dx.doi.org/10.1136/bmj.f2610]
43. Hou W, Lv J, Perkovic V, Yang L, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: A systematic review and meta-analysis. Eur Heart J 2013;34(24):1807-1817. [http://dx.doi.org/10.1093/eurheartj/eht06]
44. Schnohr P, Scharling H, Jensen JS. Intensity versus duration of walking, impact on mortality: the Copenhagen City Heart Study. Eur J Cardiovasc Prev Rehabil 2007;14(1):72-78. [http://dx.doi.org/10.1097/HJR.0b013e3280144470]
45. Lee IM, Paffenbarger RS Jr. Associations of light, moderate, and vigorous intensity physical activity with longevity: The Harvard Alumni Health Study. Am J Epidemiol 2000;151(3):293-299. [http://dx.doi.org/10.1093/oxfordjournals.aje.a010205]
46. Opie LH. Living Longer, Living Better. Exploring the Heart-Mind Connection. Oxford: Oxford University Press, 2011:36.
47. Gotto A Jr, Opie LH. Lipid-modifying and anti-atherosclerotic drugs. In: Opie LH, Gersh BJ, eds. Drugs for the Heart. 7th ed. Philadelphia: Elsevier Saunders, 2009:353.